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Introduction
The medicinal use of gold can be traced back through many 
centuries, although historical proof for its efficacy is lacking.1 
Today’s evidence supports the systemic use of gold salts in man 
for the treatment of inflammatory arthritis2-5 but the practical 
utility is decreased by the potential cytotoxic side effects.6 There 
are reports of reduced pain and improved limb use in human 
and canine patients with arthropathies that receive gold beads 
implanted at acupuncture sites.7,8 The suggested beneficial effect 
is likely attributable to the local liberation of gold ions that can 
be traced to the surrounding connective tissues.9
As an alternative to the use of gold salts or locally applied gold 
particles, intra-articular administration of gold nanoparticles 
(AuNPs) has recently been investigated.10,11 These studies showed 
that AuNPs reduced synovial pro-inflammatory cytokines and 
cellular infiltrates and resulted in fewer clinical and radiographic 
abnormalities in a rodent model of collagen induced arthritis. 
In addition to a potential primary therapeutic use, AuNPs may 
also serve as carriers for local drug delivery and thereby increase 
the half-life of therapeutic levels of select drugs.12-14 Future 
Gold nanoparticles (auNps) have great potential as carriers for local drug delivery and as a primary therapeutic for 
treatment of inflammation. here we report on the auNp-synovium interaction in an ex vivo model of intra-articular 
application for treatment of joint inflammation. sheets of porcine femoropatellar synovium were obtained post mortem 
and each side of the tissue samples was maintained in a separate fluid environment. permeability to auNps of different 
sizes (5–52 nm) and biomarker levels of inflammation were determined to characterize the ex vivo particle interaction 
with the synovium. Lipopolysaccharide or recombinant human interleukin-1β were added to fluid environments to assess 
the ex vivo effect of pro-inflammatory factors on permeability and biomarker levels. The synovium showed size selective 
permeability with only 5 nm auNps effectively permeating the entire tissues’ width. This process was further governed by 
particle stability in the fluid environment. auNps reduced matrix metalloproteinase and lactate dehydrogenase activity 
and hyaluronic acid concentrations but had no effect on prostaglandin e2 levels. exposure to pro-inflammatory factors 
did not significantly affect auNp permeation or biomarker levels in this model. results with ex vivo tissue modeling of 
porcine synovium support an anti-inflammatory effect of auNps warranting further investigation.
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intra-articular application of AuNPs will require specific knowl-
edge of the synovial barrier-carrier interaction, including the 
permeability of the synovium to nanoparticles. Ex vivo tissue 
modeling techniques are well established in a variety of biomedi-
cal fields and form an important step in advancing bench top 
discoveries to in vivo applications and ultimately clinical prac-
tice.15,16 Advantages associated with their use include the con-
trol and standardization of the experimental environment while 
maintaining physiologic tissue responses.17,18 We are not aware of 
the use of similar techniques as described herein for modeling of 
synovial pathophysiology. On the basis of these techniques we 
report on the AuNP-synovium interaction and synovial mem-
brane permeation for potential future intra-articular application 
in treating arthritis. We hypothesized that by using ex vivo tissue 
modeling methods we could evaluate the size-selective permea-
bility of the synovium to AuNPs and determine whether this per-
meability pattern changes in the presence of lipopolysaccharide 
(LPS) or interleukin-1β (IL-1β), activators of synovial inflam-
matory cascades.19,20 Furthermore, we hypothesized that tissues 
exposed ex vivo to AuNPs would show a reduction in inflamma-
tory biomarkers compared with control tissues.
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1.11–14.08 mg/L). The average percent reduction in articular 
AuNP concentration was 23% (SEM 2.63%) for 5 nm, 22.6% 
(SEM 5.5%) for 10 nm, 3.2% (SEM 2.88%) for 20 nm and 7.2% 
(SEM 3.73%) for 52 nm AuNPs.
Dry state particle size significantly determined the amount 
of AuNP diffusion assessed by both histomorphometry and 
cumulative and sequential elemental gold concentrations (p = 
0.001). While lesser diffusion was appreciated with greater 
AuNP size, only comparisons with 5 nm particles reached sig-
nificance. This illustrated the fact that effective tissue perme-
ation only occurred with the smallest particles (Fig. 2). Next 
to particle size, the time of sampling also exerted a significant 
effect in all kinetic data analyses (p < 0.001) and this was 
best appreciated with the use of the 5 nm particles (Fig. 3). 
As stated previously, this is explained by 5 nm particles per-
meating through the entire tissues’ width, which at the most 
measured 379.5 μm (SEM 20.9 μm) and at the least 216.3 μm 
(SEM 17.4 μm).
Results
Details on experimental groups and sampling protocol are 
shown in Figure 1. Tissues exposed to AuNPs received either 
pro-inflammatory factors (Group AuNP/P-Infl), LPS and IL-1β 
or their respective vehicle (Group AuNP/V). Groups that were 
not exposed to AuNPs (control group) received either IL-1β (C/
IL-1β) or IL-1β vehicle (C/IL1V).
AuNP permeation through the synovium. AuNP permeation 
through the synovial membrane from the articular to the non-
articular chamber compartment was evaluated on the basis of the 
following measures: The AuNP dose reduction (H1 minus H2 
sample concentration), the sequential and cumulative amount 
of diffusing elemental gold (individual or sum of sample con-
centrations S1-S10) and the histomorphometric quantitation of 
gold specific tissue stains. The average AuNP dose (H1 sample) 
was 7.63 mg/L (range 3.17–18) which at the end of experiments 
(H2 sample) was reduced to 6.48 mg/L (H2 sample; range 
Figure 1. experimental protocol. (A) schematic of the experimental groups. (B) schematic of the experimental procedures (auNps, gold nanoparticles; 
au, elemental gold; Lps, lipopolysaccharide; LpsV, Lps vehicle; IL-1β, interleukin-1β; IL1V, interleukin-1β vehicle; MMp, matrix metalloproteinase; LDh, 
lactate dehydrogenase; ha, hyaluronic acid; pGe2, prostaglandin e2).
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Examples of the size-dependent perme-
ation of the synovial membrane are demon-
strated in Figure 4. Transmission electron 
microscopy was performed as an alternate 
method to gold staining to validate the 
presence of AuNPs in tissues, confirming 
the presence of AuNPs in extra- and intra-
cellular locations. Relatively few particles 
were observed in the interstitium, presum-
ably due to particle loss during sample 
preparation. Figure 5 shows synoviocytes 
and surrounding interstitium after expo-
sure to 5 nm AuNPs and demonstrates 
that particles were diffusely distributed 
throughout the cytoplasm. This observa-
tion suggests uptake of the AuNPs through 
the cytoplasmic membrane independent of 
endocytosis (Fig. 5C). Evidence sugges-
tive of possible endosomal uptake in the 
form of a membrane bound electron lucent 
vesicle containing AuNPs (white arrow) 
and mitochondrial penetration (asterisk) 
was also seen (Fig. 5D). Extracellular loca-
tions of larger agglomerates are indicated 
by black arrows (Fig. 5A and B). Nuclear 
penetration was not observed.
Effect of pro inflammatory factors 
on AuNP permeation. When examin-
ing the individual effect of the two pro-
inflammatory factors (LPS or IL-1β) and 
their vehicle controls (LPSV or IL1V) 
on synovial permeability, chambers con-
taining IL-1β vehicle (1% bovine serum 
albumin solution) displayed significantly 
greater sequential and cumulative AuNP 
permeation (p = 0.001). Figure 3 illus-
trates this effect for 5 nm AuNP per-
meation. When compared with each of 
their vehicle controls, neither of the two 
factors exerted a measurable effect on ex 
vivo synovial AuNP permeation. With 
respect to the effect of “time,” a signifi-
cant difference in permeating AuNPs 
concentrations over baseline values was 
noted for vehicle and IL-1β use, 105 min 
and 90 min respectively after dosing 
(p = 0.0119; p = 0.0232).
AuNP effect on biomarkers of 
inflammation. To assess the effect of 
permeating AuNPs on synovial tissues, 





; matrix metalloproteinases, 
MMP), cell integrity (lactate dehydro-
genase, LDH) and synoviocyte function 
(hyaluronic acid, HA) were assessed in 
non-articular fluid samples. There was 
Figure 2. size dependent permeation of the synovial membrane assessed by histomorphometry. 
Bars represent the average surface area of the gold specific tissue stain (pixel2) for each size of 
gold nanoparticle (auNp) used (5, 10, 20 and 52 nm). significance was reached for all compari-
sons with 5 nm auNps (p < 0.001). error bars represent the standard error for the mean.
Figure 3. Time-dependent permeation of 5 nm gold nanoparticles through the synovial mem-
brane. a significant difference in synovial auNp permeation was observed between chambers 
receiving IL-1β vehicle and Lps or Lps vehicle. significantly different permeation curves (p < 0.05) 
are indicated by different letters. stars above time points indicate when and for what group sample 
concentrations were significantly different from baseline values. error bars represent the standard 
error for the mean (Lps, lipopolysaccharide; IL-1β, interleukin-1β; V, vehicle).
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and lower HA concentrations (p < 0.001). For LDH and HA this 
significance was limited to individual comparisons with Group 
C/IL1V (Fig. 6). Positive correlations between biomarkers were 
no significant association of the experimental group with PGE
2
 
concentrations. Tissues that were exposed to AuNPs showed sig-
nificantly less MMP (p < 0.001) and LDH (p < 0.001) activity 
Figure 4. representative images of the size dependent permeation of the synovial membrane. Tissues had been exposed to (A) 5 nm auNps, 
(B) 10 nm auNps, (C) 20 nm auNps and (D) 52 nm auNps prior to gold enhancement. Five nanometer auNps can be seen penetrating all tissue layers. 
elemental gold appears black (auNps, gold nanoparticles; scale bar = 50 μm).
Figure 5. representative transmission electron microscopic images of auNp localization. By enlarge auNps were scattered throughout the cytoplasm 
and organelles of synoviocytes including the smooth endoplasmatic reticulum and mitochondria (C and D). extracellular location of large particle ag-
glomerates were also appreciated (A and B). evidence for larger auNps agglomerates in endosomes (white arrow) is illustrated in (D).
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with AuNPs added. PGE
2
 and HA concentration standards with 
AuNPs added resulted in an average increase equal to 56 and 
4.5% of the value when AuNPs were not present (corrected for 
dilution). MMP and LDH activity decreased by 22.7 and 0.77%.
Effect of pro-inflammatory factors on biomarkers of inflam-
mation. No significant difference in biomarker levels was 
observed between tissues exposed to pro- inflammatory factors 
and their controls (Fig. 6).
Histopathology of the synovial membrane. Histologic 
changes were assessed on the basis of a semi-quantitative grad-
ing scale for which examples are shown in Figure 7. Notable ex 
vivo changes were limited to synovial ulcerations. Only one of 
the synovial membrane samples was categorized as edematous 
(Grade 2). When Group C/IL1V was considered the reference 
standard, the proportion of histologic grades differed signifi-
cantly among the three remaining groups with 63% in Group 
AuNP/P-Infl, 59% in Group AuNP/V and 0% in Group C/
IL-1β showing ulceration greater than 5% of the sections’ surface 
limited to LDH with MMP activity (correlation coefficient: 
0.386; p < 0.001) and HA concentrations (correlation coefficient 
0.286; p = 0.016). When tissues were exposed to AuNPs and pro-
inflammatory factors, LDH, MMP and HA measures were on 
average 35.4%, 36.4% and 48% of the value when no AuNPs 
were present; when tissues were exposed to AuNPs alone these val-
ues were 49.6%, 35.8% and 66.1% respectively of vehicle treated 
tissues.
AuNPs size had a significant effect on MMP activity (p = 0.0046; 
significant comparisons: 10 vs. 20 nm AuNPs/p = 0.0285; 10 
vs. 5 nm AuNPs/p = 0.0082), LDH activity (p < 0.001; 10 vs. 
5 nm AuNPs/p < 0.001; 20 vs. 5 nm AuNPs/p = 0.0226) and 
HA concentrations (p = 0.038; 10 vs. 20 nm AuNPs/p = 0.0310). 
However, these significant differences did not translate into 
relevant conclusions regarding the effect of particle size on 
biomarkers.
To evaluate the effect of AuNPs on laboratory techniques 
and validate results, select biomarker analyses were repeated 
Figure 6. Molecular biomarkers by experimental group Group auNp/p-Infl: Tissues exposed to auNps and pro-inflammatory factor Group auNp/V: Tis-
sues exposed to auNps and vehicle; Group c/IL1V: synovium exposed to Interleukin-1β vehicle only; Group c/IL-1β: synovium exposed to Interleukin-
1β. error bars represent the standard error for the mean. Bars above group comparisons indicate significance (p < 0.05).
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contrast to our expectations, ex vivo exposure to pro-inflamma-
tory factors did not significantly affect biomarker levels. This is 
likely the result of the inherent activation associated with tissue 
collection that cannot be surpassed by further ex vivo stimula-
tion. A similar phenomenon has been observed when using por-
cine gastrointestinal tissues, which required pre-treatment with 
a cyclooxygenase inhibitor to study subsequent prostaglandin-
dependent outcome measures.23 The porcine and murine IL-1β 
cDNA sequence show 74% homologies with the human form24 
and use of human recombinant IL-1β has been effective in tis-
sues from both species.25-30 Nevertheless, heterology between 
human and porcine cytokines should also be considered in the 
absence of a significant IL-1β effect. Concerning the selection of 
IL-1β as the pro-inflammatory factor, the role of this cytokine in 
joint disease has been well documented.20,31-35 The dose applied 
was chosen taking previous in vitro36,37 and in vivo heterologous 
use of recombinant human IL-1β into consideration and adjust-
ing for the typical fluid volume in injected joints vs. the Ussing 
chamber system.38,39 Despite these considerations the dose selec-
tion may have been inappropriate. The authors are aware of these 
specific limitations and future investigations will include the use 
of recombinant porcine IL-1β and dose-response experiments to 
further elucidate the pro-inflammatory potential of this cytokine 
in an ex vivo model of synovial tissue.
A previous in vivo study on rabbit synovium illustrated a loss 
in barrier function and increase in diffusion of hyaluronic acid 
molecules with enzymatic degradation of extracellular matrix 
proteins.40 In our study, use of IL-1β did not initiate a similar 
effect on AuNP permeation. This may have been caused in part 
by factors described in the preceding section. However, inability 
(p = 0.0087). However in statistical analyses the histologic grade 
had no effect on biomarker levels.
Particle stability in the fluid environment. The hydrody-
namic size of AuNPs in components of articular fluid media was 
assessed to interpret the particles’ ability to permeate tissues in 
chamber experiments in the context of physical and functional 
size. When AuNPs were added to articular media, an increase 
in hydrodynamic size was noted which was attributed to par-
ticle agglomeration. This effect was most pronounced for 5 nm 
particles and when LPS was added to the media (Table 1). 
Hydrodynamic sizes of AuNPs in IL-1β vehicle containing fluids 
remained relatively unchanged confirming a stabilizing effect of 
the 1% bovine serum albumin solution and supporting findings 
shown in Figure 3.
Discussion
Confirming the authors’ hypothesis, samples of synovial mem-
brane were successfully mounted in the Ussing chamber and 
demonstrated size selective permeability to AuNPs both on 
inductively coupled plasma mass spectrometry and histomor-
phometry. However, effective permeation of tissue samples mea-
sured with mass spectrometry was only observed using AuNPs of 
5 nm dry state size. Previous in vivo work in rabbit stifles suggests 
that effective matrix pore size ranges between 66 and 118 nm 
allowing smaller molecules to leave the joint environment freely.21 
Our observation that 52 nm particles were unable to breach the 
subintima may be in line with these findings but the propensity 
of bare AuNPs to agglomerate and result in greater hydrody-
namic size may make this conclusion less relevant (Table 1).22 In 
Figure 7. representation of synovial ulceration. The degree of synovial ulceration was graded based on the estimated percentage of synovium miss-
ing over the length of the sample evaluated. (A) shows a representation of the synovial lining at 60× magnification that was considered normal; a 
continuous lining of synovial cell is present. (B) represents tissue at the same magnification with ulceration of the synovium; a discontinuous lining of 
synovial cell is observed over the subsynovial connective tissue (bar = 30 μm).
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increase HA production via activation of synthases located on the 
inner surface of cell membranes.50 In this process synthases con-
tinuously assemble disaccharide molecules to form longer chains, 
extruding from the cell surface into the extracellular space.51 
Possible explanations for the observed reduction in HA levels 
may include AuNP dependent inhibition of synthases or IL-1β 
adsorption.52 Alternatively, low concurrent LDH activity levels 
may be indicative of fewer HA chains being dissociated from 
the cell surface due to greater membrane stability when AuNPs 
were present. However, this potential explanation is contradicted 
by the histological finding that exposure to AuNPs resulted in 
greater synovial ulceration.
As alluded to previously, nanoparticles have the ability to 
interfere with cellular function based on their reactivity and 
binding of key proteins. This reportedly includes vascular endo-
thelial growth factor and IL-1β.10,52,53 Exposure of LPS-activated 
macrophages, a cell line similar to synoviocytes (Type A), to 
polyethylene glycol coated AuNPs suggests that direct effects 
also include inhibition of inducible nitric oxide synthase expres-
sion.54 Besides these effects, administration of gold particles 
may lead to gold ion elution9,55-58 which in turn could result 
in therapeutic effects comparable to those of other gold-based 
pharmaceuticals. Most importantly these effects could include 
inhibition of NF-kappa B59-61 and downregulation of the p38 
MAPK pathway.62 In the present experiments, synovial tissue 
samples were maintained in Ussing chambers for 195 min. 
From other applications it is known that treatment-induced 
changes in PGE
2
 concentrations occur within this experimental 
time frame.63,64 Whether this time is sufficient for the observed 
changes in HA or MMP levels to develop remains to be deter-
mined but causes that involve downstream interference at the 
level of enzyme function rather than the signaling pathway may 
be more plausible. In fact, significant in vitro IL-1β activation of 
intracellular signaling pathways to increase MMP synthesis was 
detected one hour post stimulation.65 Recent evidence obtained 
in vivo demonstrated a significant change in MMP and PGE
2
 
concentrations 4 h post IL-1β exposure.66 Taken together this 
may suggest that our experimental time frame may have been 
too short to illustrate significant upstream effects on biomarker 
concentrations.
Given that in our experiments, ability to permeate tissues was 
not associated with a greater effect on biomarkers, in vivo use of 
larger AuNPs may be preferred in an attempt to minimize sys-
temic absorption and potential toxic side effects.67-69 Support for 
this conclusion may be found in the only other study available for 
comparison, which demonstrated that a positive in vivo treatment 
to recruit vascular effector cells promoting tissue inflammation 
and degradation in an ex vivo model may also be involved. In 
this study LPS exposure appeared to reduce synovial permeabil-
ity to AuNPs compared with IL-1β use. However this effect was 
predominantly driven by the absence of IL-1β vehicle, leading to 
particle agglomeration and reduced permeation.
Nanoparticles show complex behavior in biological systems 
based on their composition, size, shape, surface charge and chem-
istry.41 Derived from the intensity of scattered light the hydro-
dynamic size describes the dimension of a spherical particle in 
fluid media surrounded by the solvation layer.41 It provides infor-
mation on the particle’s stability or agglomeration state which is 
dependent on surface charge and ultimately the particle’s interac-
tions with different fluid components (ions and proteins).42 From 
the hydrodynamic sizing of AuNPs in different chamber fluid 
components it can be concluded that particles agglomerated in 
saline solution and that this was increased with the presence of 
LPS and decreased with the use of 1% bovine serum albumin 
solution. These effects have in part been reported previously22,43,44 
and are supported by our conclusion that presence of IL-1β vehi-
cle increased AuNP permeation.
From the results it may be further concluded that AuNPs 
promoted cell viability (reduced LDH activity),45 reduced MMP 
activity and HA concentrations while exerting no significant 
effect on PGE
2
 concentrations. These findings need to be inter-
preted with caution as evidenced by the limited investigation of 
the AuNP effect on performed assays. Nanoparticles have the 
ability to interfere with biological assays based on adsorbance 
of reagents or reporter dyes, optical absorbance and interaction 
with the primary analyte.45-47 Although LDH assay performance 
was not affected by AuNPs in our study, this potential bias has 
been demonstrated for other nanoparticles.48 In contrast, PGE
2
 
assays overestimated true concentrations by an average of 56%. 
Prostaglandin immunoassays are based on the competitive anti-
body binding of sample PGE
2
 and acetylcholinesterase bound 
PGE
2
 molecules. Enzyme driven conversion of Ellman’s reagent 
results in a yellow color reaction that is inversely proportional 
to sample PGE
2
 concentrations. Considering the great affin-
ity of nanoparticles to acetylcholinesterase, overestimation of 
the actual PGE
2
 content was likely caused by AuNP-dependent 
enzyme inhibition.49 Assuming that PGE
2
 concentrations are in 
fact lower than reported, they may be in line with the observed 
trend that AuNPs reduce biomarkers of inflammation.
Based on the absence of a marked nanoparticle effect on HA 
assay performance, the conclusion that AuNPs reduced HA con-
centrations is likely valid. IL-1β stimulation has the potential to 
Table 1. hydrodynamic size of gold nanoparticles (auNps) in different fluid environments
Dry state size 
(nm)
In distilled water 
(nm)
In simulated  
chamber fluid (nm)
In simulated chamber 
fluid + IL1β (nm)
In simulated chamber fluid 
+ IL1β-C (nm)
In simulated chamber 
fluid + LPS (nm)
5 30 700 157 72 790
10 24 432 98 78 495
20 25 345 69 62 489
52 64 284 88 84 293
IL1β-c, interleukin-1β vehicle; Lps, Lipopolysaccharide.
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hemi-patella. Continuous tissue samples were obtained by blunt 
dissection undermining the synovial membrane in that area. 
Within one hour, samples were transported to the laboratory 
in oxygenated (95% O
2
 and 5% CO
2
) Ringer’s solution (323.9 




- 0.3, Ca2+ 1.2, 
Mg2+ 0.7, HCO
3
- 24 mmol/l) at room temperature and mounted 
in Ussing chambers with a 1.14 cm2 aperture.
Ussing chambers. Synovial tissue samples were bathed on the 
intima (articular) and subintima (non-articular) side with 5 ml 
of oxygenated Ringer’s solution maintained at 37°C via water-
jacked reservoirs. Glucose was added to the non-articular side 
and mannitol to the articular side (10 mmol/L) of the Ussing 
chamber for oncotic balance. At time “0,” the articular side of the 
chambers were either treated with 100 ng/ml of LPS in Ringer’s 
solution (from E. coli 0111:B4, L4130, Sigma-Aldrich), 20 ng/ml 
of human recombinant IL-1β (SRP3083, Sigma-Aldrich) sus-
pended in a 1% solution of bovine serum albumin or vehicle 
control solution (Ringer’s solution or bovine serum albumin solu-
tion). After one hour the articular fluid compartments were either 
dosed with an unconjugated spherical gold nanoparticle (AuNP) 
solution (Nanopartz, Accurate Spherical Gold Nanoparticles, 
mean particle sizes 5, 10, 20 and 52 nm) that was previously 
sonicated for one minute or with a saline control. Subsequently 
the bathing fluid of the non-articular side was sampled (1 ml) 
and every 15 min thereafter until completion of the experiment 
(S1–S10, 60–195 min post tissue mounting). Fluid of the articu-
lar compartment was sampled twice (0.5 ml at time “60” (H1) 
and “195” (H2)). Non-articular reservoir fluids were replenished 
using the Ringer’s and glucose solution. All fluid samples were 
immediately frozen in liquid nitrogen and stored at -80°C until 
they were thawed on ice, vortexed and further analyzed.
AuNP hydrodynamic size. Samples of the nanoparticle dos-
ing solution were mixed with the simulated articular fluid media 
or distilled water (1:4), sonicated for 5 min and the hydrody-
namic size was assessed in a 100 μl sample using dynamic light 
scattering methods (ZetaSizer, Malvern Instruments). Size 
measurements were averaged across 60 repeated measurements 
obtained in triplicate runs of the same sample.
AuNP quantitation. Elemental gold concentration in articu-
lar and non-articular fluid samples was determined using induc-
tively coupled plasma mass spectrometry (Varian 820) with an 
estimated detection limit of 0.1 μg/L. Gold concentrations of 
samples (S1-S10) were summed to give a cumulative amount of 





) quantitation. A competitive ELISA 
kit (Cayman Chemical, Item No 514010) was used with samples 
analyzed in triplicate. Outliers that resulted in a coefficient of 
variance greater than 30% were excluded from the analysis.
Hyaluronic acid (HA) quantitation. An enzyme linked bind-
ing protein assay was used to determine HA concentrations 
(ng/ml) of articular fluid samples in duplicate analyses (Corgenix 
Inc., 029-001).
The effect of gold particles on the PGE
2
 and HA assays was 
determined by running the standards (S4 and medium molecu-
lar weight HA) with and without AuNPs added. This was per-
formed in duplicate for each nanoparticle size.
effect of AuNPs was also not dependent on particle size.11 
Interestingly, next to other dramatic positive effects of AuNPs in 
this study, a reduction in cell necrosis was also reported, further 
validating our observation of reduced LDH activity.
Regarding systemic side effects, murine studies suggest that 
after intravenous administration biodistribution of AuNPs is in 
part size dependent and that particles predominantly accumu-
late in the liver, lung and spleen but can also be found in the 
brain if smaller than 50 nm.67 Gene expression profiling of liver 
tissue 30 min after intravenous administration of polyethylene 
glycol-coated AuNPs (4.3 mg/kg) showed that less than 0.5% 
of all genes were specifically expressed and that these genes were 
responsible for apoptosis, cell cycle, inflammation and metabolic 
processes.70 Seven days after intravenous administration and 
depending on the dose administered (0.17 to 4.3 mg/kg) an aver-
age of 2.6 to 8.5% of liver cells underwent apoptosis compared 
with 0.4% in controls.71 Collectively, these studies demonstrate 
the potential for systemic side effects following AuNP adminis-
tration. While doses in our investigation should be considered 
high in light of the amount of tissue exposed (0.04 mg/1.14 cm2) 
they are low in the context of total body exposure and potential 
systemic biodistribution (0.00148 mg/kg; by approximation).
In summary, the results reported herein suggest that intra-
articular application of 5 nm AuNPs (dry state size) leads to par-
ticle permeation through the joint capsule, facilitating systemic 
bioavailability. Based on this and previous work it is further 
expected that nanoparticles leave the joint cavity in a size depen-
dent manor either unassisted or within cells and accumulate in 
the reticuloendothelial system.21,72 Beyond a yet to be determined 
size but likely in the range of 50 nm, we anticipate AuNPs to be 
largely retained within the synovial environment. We consider 
this to be a relevant characteristic in light of the potential use of 
AuNPs as drug carriers or primary therapeutics and the poten-
tial for systemic side effects. In this investigation, we associate 
AuNP administration with a significant reduction in inflamma-
tory biomarkers except PGE
2
, but limitations of this study have 
to be considered. Future studies will seek to validate our ex vivo 
experiments by including more analytical time points, in vivo 
exposure to homologous cytokines and AuNP while still collect-
ing ex vivo outcome data. This approach will minimize potential 
bias of AuNPs on assays, increase the stimulatory effect of pro-
inflammatory cytokines and allow time dependent assessment of 
biomarkers.
Materials and Methods
Tissue acquisition. Synovial membrane samples were obtained 
from pigs sacrificed at the authors’ institution for unrelated 
research or teaching purposes approved by the Institutional 
Animal Care and Use Committee. Animals weighed between 22 
and 31 kg and were euthanatized with an intravenous barbiturate 
overdose. In each animal synovial membrane was harvested from 
one femoropatellar joint. To do so the patella was released from 
its proximal and distal attachments and bisected to open the joint 
in a “barn-door” fashion resulting in two areas of preserved syno-
vial membrane located between each femoral trochlear ridge and 
www.landesbioscience.com Tissue Barriers e24314-9
7. Nejrup K, Olivarius NdeF, Jacobsen JL, Siersma V. 
Randomised controlled trial of extraarticular gold 
bead implantation for treatment of knee osteoarthri-
tis: a pilot study. Clin Rheumatol 2008; 27:1363-9; 
PMID:18500437; http://dx.doi.org/10.1007/s10067-
008-0918-9.
8. Jaeger GT, Larsen S, Søli N, Moe L. Double-blind, 
placebo-controlled trial of the pain-relieving effects 
of the implantation of gold beads into dogs with hip 
dysplasia. Vet Rec 2006; 158:722-6; PMID:16731702; 
http://dx.doi.org/10.1136/vr.158.21.722.
9. Danscher G. In vivo liberation of gold ions from 
gold implants. Autometallographic tracing of gold in 
cells adjacent to metallic gold. Histochem Cell Biol 
2002; 117:447-52; PMID:12029492; http://dx.doi.
org/10.1007/s00418-002-0400-8.
10. Tsai CY, Shiau AL, Chen SY, Chen YH, Cheng 
PC, Chang MY, et al. Amelioration of collagen-
induced arthritis in rats by nanogold. Arthritis Rheum 
2007; 56:544-54; PMID:17265489; http://dx.doi.
org/10.1002/art.22401.
4. Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, 
Fitzgerald A, Canvin J; METGO Study Group. A 
48-week, randomized, double-blind, double-observer, 
placebo-controlled multicenter trial of combination 
methotrexate and intramuscular gold therapy in rheu-
matoid arthritis: results of the METGO study. Arthritis 
Rheum 2005; 52:1360-70; PMID:15880810; http://
dx.doi.org/10.1002/art.21018.
5. Smolen JS, Landewé R, Breedveld FC, Dougados M, 
Emery P, Gaujoux-Viala C, et al. EULAR recommen-
dations for the management of rheumatoid arthritis 
with synthetic and biological disease-modifying anti-
rheumatic drugs. Ann Rheum Dis 2010; 69:964-
75; PMID:20444750; http://dx.doi.org/10.1136/
ard.2009.126532.
6. Sander O, Herborn G, Bock E, Rau R. Prospective six 
year follow up of patients withdrawn from a randomised 
study comparing parenteral gold salt and methotrexate. 
Ann Rheum Dis 1999; 58:281-7; PMID:10225812; 
http://dx.doi.org/10.1136/ard.58.5.281.
References
1. Higby GJ. Gold in medicine: a review of its use in 
the West before 1900. Gold Bull 1982; 15:130-
40; PMID:11614517; http://dx.doi.org/10.1007/
BF03214618.
2. Rau R. Have traditional DMARDs had their day? 
Effectiveness of parenteral gold compared to bio-
logic agents. Clin Rheumatol 2005; 24:189-202; 
PMID:15940552; http://dx.doi.org/10.1007/s10067-
004-0869-8.
3. Hamilton J, McInnes IB, Thomson EA, Porter D, 
Hunter JA, Madhok R, et al. Comparative study of 
intramuscular gold and methotrexate in a rheumatoid 
arthritis population from a socially deprived area. 
Ann Rheum Dis 2001; 60:566-72; PMID:11350844; 
http://dx.doi.org/10.1136/ard.60.6.566.
tissue’s maximum and minimum width in each image and mea-
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Histology. A board certified pathologist, blinded to the iden-
tity of each slide graded the degree of synovial ulceration (0 = no 
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to 75% and 4 = more than 75% of the synovial surface) and 
sub-synovial connective tissue edema (0 = no edema; 1 = mild; 
2 = moderate; 3 = severe). Tissue samples that were neither stimu-
lated nor had gold exposure (Group C/IL1V) were used as a refer-
ence standard.
Transmission electron microscopy. Synovial samples were 
fixed in 4F:1G, dehydrated in a graded series of ethanol and 
embedded in Spurr resin.74 Semithin sections, 0.5 μm thick, 
stained with 1% toluidine blue in 1% sodium borate, were 
examined under a light microscope. Ultrathin sections, 90 nm 
thick, of appropriate blocks were examined with a FEI/Philips 
EM 208S transmission electron microscope. Only tissue samples 
exposed to 5 nm AuNPs were examined.
Statistical analyses. A Fisher’s exact test was used to com-
pare proportions of histologic grades by experimental group 
(AuNP/P-Infl, AuNP/V, C/IL-1β). Using the mixed proce-
dure (SAS 9.2, SAS Institute Inc.) the significance of individ-
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2
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MMP, LDH, gold stain area, cumulative elemental gold con-
centration). Relevant comparisons were performed using an 
LSMEANS statement and the Tukey adjustment for multiple 
testing. Relationships between dependent variables were investi-
gated using Pearson correlations.
Kinetic data obtained with mass spectroscopic gold determi-
nations were analyzed using repeated measures ANOVA with 
“time” as the repeated variable. For all statistical analyses the 
critical p value was set at 0.05.
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Matrix metalloproteinase (MMP) activity. Using a previously 
described technique73 MMP activity (MMP 2, 3, 7, 9, 12 and 13) 
was determined using an activatable near infrared (NIR) fluo-
rescent probe added to articular fluid samples in a 96-well plate 
(MMPSense 750 FAST, PerkinElmer) and a NIR fluorescence 
reader (Ivis Lumina II, PerkinElmer).
The effect of AuNPs on MMP measurements was investigated 
by repeated analysis of three fluid samples with and without 5 nm 
AuNPs added.
Lactate dehydrogenase (LDH) activity. A toxicology assay 
kit (TOX7, Sigma-Aldrich) was used to determine the enzyme’s 
activity in articular fluid samples based on a stoichiometric colo-
rimetric reaction measured at a wavelength of 490 nm. Samples 
of Group C/IL1V were rerun in duplicate with AuNPs (all sizes) 
added.
Tissue processing. Tissue samples were fixed using 
MacDowell’s and Trump’s 4F:1G solution, embedded in paraffin 
and three cross sections per synovial membrane were acquired. 
One section was stained with hematoxylin and eosin (H&E) 
only, two underwent autometallographic gold enhancement 
for 20 min (Goldenhance-LM/Blot, Nanoprobes) and one of 
these was later also stained with H&E. Tissue samples were also 
embedded in Spurr resin followed by ultrathin sectioning for 
transmission electron microscopy.
Histomorphometry. Slides were anonymized, randomized 
and for each synovium sample, the entire length of the sample 
was photographed at 10× and 40× using an Olympus DP 25 
digital microscope camera with the CellSens digital imaging 
software mounted on an Olympus BH 41 microscope (Olympus 
Corporation, Tokyo, Japan). Using Adobe Photoshop CS4 
(PhotoshopCS4; Adobe Systems) and via batch processing, 40× 
images were converted to 6,000 × 4,500 pixels (100 pixels/cm) 
and to black and white in order to highlight the gold particle. 
The batch processing procedure allowed the same setting to be 
applied to all images in a given data set. The best setting was 
determined empirically by testing images with the lowest and 
highest amount of gold particles. Finally, images were thresh-
olded in the “intermodes” setting and the area fraction covered 
with the gold particles, expressed as a percentage of the picture 
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